At present, both the Royal Dutch Pharmacists Association Pharmacogenetics Working Group and draft guidance from the National Institute for Health and Care Excellence in England recommend routine CYP2C19 genotyping in patients who have had a stroke.34 This evidence concerns the gene CYP2C19 and Stroke.